ライフサイエンスコーパス: monoamine

1 (5-HT1) on pericytes, despite the absence of monoamines.

2 pendent modulation of cortical efficiency by monoamines.

3 ades monoamine neurotransmitters and dietary monoamines.

4 tress, influences apoptosis, and metabolizes monoamines.

5 ing and eliminated the inhibitory actions of monoamines.

6 However, little is known regarding how monoamines affect OFC neuron excitability or whether thi

7 el tone adapts to the loss of neuron-derived monoamines after spinal cord injury (SCI) in rats.

8 e area, glial activation, CNS cytokines, and monoamine and amino acid neurotransmitters were quantifi

9 However, individuals who take monoamine and diamine oxidase inhibitors drugs should be

10 The monoamine and neuropeptide networks exhibit distinct top

11 lates nociception through the interaction of monoamine and neuropeptide signaling pathways.

12 diamines that are selectively detected over monoamines and alpha-amino acids.

13 xicity results in long-lasting depletions of monoamines and changes in basal ganglia function.

14 AANAT1 acetylates monoamines and inactivates them, and we found that AANAT

15 synaptic volume transmission, especially via monoamines and neuropeptides, is also critical to brain

16 Here we show that natural monoamines and synthetic amines inhibit pDC activation b

17 The presence of monoamines and their cofactors (the pterins and vitamin

18 (HPLC) approaches to determine CSF levels of monoamines and their cofactors.

19 S9-2) plays a key modulatory role in opioid, monoamine, and other G-protein-coupled receptor response

20 The OFC is extensively innervated by monoamines, and drugs that target monoamine receptors ha

21 er neuromodulatory control by acetylcholine, monoamines, and other signaling molecules.

22 these studies could potentially affect other monoamines, and the scarcity of imaging evidence on dopa

23 Monoamines are analyzed by HPLC with coulometric electro

24 Together, these findings show that monoamines are important modulators of lOFC excitability

25 We found that invasion of monoamine, basal forebrain, thalamocortical, and cortico

26 ssant, imipramine, and a rapidly acting, non-monoamine-based antidepressant, ketamine, in mice subjec

27 fully modulating the amphiphilic nature of a monoamine-based GAEL, we can generate a potent triamino

28 We compared the effects of a conventional monoamine-based tricyclic antidepressant, imipramine, an

29 r AANAT1 and astrocytes in the regulation of monoamine bioavailability and homeostatic sleep.

30 predictive of reduced central nervous system monoamines by bioinformatics analyses and confirmed by h

31 We have mapped the putative monoamine connections, as well as a subset of neuropepti

32 (Tph2, SERT, and Pet-1) genes, and midbrain monoamine content in mice raised under control Equinox (

33 act and the mode of action involves abnormal monoamine content in trout.

34 Monoamines, cytokines, glutamate, GABA and other central

35 All three monoamines decreased current-evoked spike firing of lOFC

36 nd solitary locusts co-injected by these two monoamines displayed the same tendency as the olfactory

37 man patient-derived xenograft lines, how the monoamine dopamine influences GBM cells.

38 The role of the monoamines dopamine (DA) and serotonin (5HT) and the mon

39 ely, it is thought that, with one exception, monoamines (dopamine, serotonin, and norepinephrine) sig

40 Resultant monoamine dysregulation may underlie SAD symptomatology

41 ses of d-amphetamine (AMPH), which increases monoamine efflux in the mPFC.

42 erived hypothesis that moderate increases in monoamine efflux would enhance attractor stability, wher

43 are less efficacious than others in inducing monoamine efflux).

44 2 (VMAT2) substrate that selectively traces monoamine exocytosis in both neuronal cell culture and b

45 helicates of different sizes from a primary monoamine, Fe(II) ions, and dialdehyde ligand strands th

46 enetic link for cannabis regulation of brain monoamine function.

47 The electrochemical similarity of these monoamines, however, confounds real-time measurements of

48 tered on neurochemical deficits, such as the monoamine hypothesis, research toward this goal has shif

49 Histamine (HA), a wake-promoting monoamine implicated in stress-related arousal states, i

50 ich is required for the vesicular storage of monoamines in both SVs and LDCVs.

51 ion among their symptoms, the implication of monoamines in depression, and the hypothesis that PrP(C)

52 Based on the role of monoamines in reconfiguring invertebrate networks, and d

53 actions by elevating extracellular levels of monoamines in the brain.

54 most efficient deamination takes place when monoamine is in the zwitterionic form (pH 9-11) or diami

55 -amines were tried for polymer modification: monoamine Jeffamine M 1000 used previously in some resea

56 pocalins with tick lipocalins that sequester monoamines, leukotrienes and fatty acids.

57 nding on the modulatory action of harmane on monoamine levels and could potentially be of therapeutic

58 e hypothesis that venlafaxine perturbs brain monoamine levels and disrupts molecular responses essent

59 ol behavioral flexibility, we found elevated monoamine levels in the PFC of CD38(-/-) adult mice.

60 arbolines including harmane modulate central monoamine levels partly through monoamine oxidase (MAO)

61 ver, TPH2 expression and activity as well as monoamine levels were unchanged in the projection areas

62 ce attractor stability, whereas high frontal monoamine levels would severely diminish it.

63 mpared intra-PFC opioid manipulations with a monoamine manipulation (d-amphetamine), in two sucrose-r

64 Computational theories propose that monoamines may exert bidirectional (concentration-depend

65 These results indicate both low monoamine metabolism and neuronal membrane dysfunction a

66 ed a genome-wide association study (GWAS) of monoamine metabolite (MM) levels in cerebrospinal fluid

67 ramine (4-hydroxyphenethylamine), which is a monoamine metabolized by monoamine oxidase (MAO), exists

68 es dopamine (DA) and serotonin (5HT) and the monoamine-metabolizing enzyme monoamine oxidase A (MAOA)

69 macologic profile that combines dose-related monoamine modulation with phosphorylation of intracellul

70 work analysis for GABA, butyrate, glutamate, monoamines, monosaturated fatty acids, and inflammasome

71 it distinct topological properties, with the monoamine network displaying a highly disassortative sta

72 ion in embryonic mid-hindbrain regions where monoamine neurons emerge.

73 nd encodes a receptor (TAAR1) that modulates monoamine neurotransmission and at which MA serves as an

74 holinergic enzymes and receptors, markers of monoamine neurotransmission as well as steroid-related t

75 on mechanism for the biological reduction in monoamine neurotransmission in Parkinson's patients.

76 drobiopterin (THB), an essential cofactor in monoamine neurotransmitter biosynthesis.

77 t currently available antidepressants target monoamine neurotransmitter function.

78 Norepinephrine (NE) is a key biogenic monoamine neurotransmitter involved in a wide range of p

79 Dopamine (DA) is a monoamine neurotransmitter responsible for regulating a

80 Dopamine (DA) is a monoamine neurotransmitter responsible for the maintenan

81 regulates neurotransmission by the biogenic monoamine neurotransmitter serotonin (5-HT, 5-hydroxytry

82 The monoamine neurotransmitter serotonin (5-hydroxytryptamin

83 termination of ultra-trace concentrations of monoamine neurotransmitter such as noradrenaline (NA) in

84 lase (AADC) deficiency is an inborn error of monoamine neurotransmitter synthesis, which results in d

85 tetrahydrobiopterin, a critical cofactor for monoamine neurotransmitter synthesis.

86 (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines, in strom

87 (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines.

88 MAOA), a mitochondria-bound enzyme, degrades monoamine neurotransmitters and dietary monoamines.

89 ng DMT at concentrations comparable to known monoamine neurotransmitters and raise the possibility th

90 Monoamine neurotransmitters are among the hundreds of si

91 Monoamine neurotransmitters are stored in both synaptic

92 ical, in-vitro application for extracellular monoamine neurotransmitters detection in living cells.

93 and amphetamines, act primarily through the monoamine neurotransmitters dopamine (DA), norepinephrin

94 atients fail to produce normal levels of the monoamine neurotransmitters dopamine and serotonin, and

95 al gland, were similar to those of canonical monoamine neurotransmitters including serotonin.

96 Modulation of neural activity by monoamine neurotransmitters is thought to play an essent

97 Monoamine neurotransmitters such as serotonin, dopamine,

98 othesis that genomic regions associated with monoamine neurotransmitters would be highly differentiat

99 in-binding site of SULT1A3, which sulfonates monoamine neurotransmitters, is modeled on that of 1A1 a

100 cus coeruleus (LC) and dorsal raphe (DR) are monoamine nuclei implicated in stress-related disorders.

101 f aversive stimuli and inhibitory control of monoamine nuclei.

102 uilding block, iron(II) chloride, and either monoamines or a diamine.

103 f aromatic l-amino acids to produce aromatic monoamines or aromatic acetaldehydes, respectively.

104 s nearly doubled and inhibition of firing by monoamines or ML297 was lost.

105 ly demonstrated direct evidence of increased monoamine oxidase (MAO) activity in the brain of a simia

106 tonin 5-HT1A receptor antagonist) as well as monoamine oxidase (MAO) and functional binding assays we

107 Previous studies have utilized monoamine oxidase (MAO) and L-3,4-dihydroxyphenylalanine

108 uate its potential to visualize and quantify monoamine oxidase (MAO) B activity in vivo.

109 late central monoamine levels partly through monoamine oxidase (MAO) inhibition.

110 endogenous imidazoline ligand agmatine, the monoamine oxidase (MAO) inhibitor harmane, the alpha(2)-

111 at cigarette smoke constituents that inhibit monoamine oxidase (MAO) may increase the reinforcing val

112 Monoamine oxidase (MAO) metabolizes cytosolic dopamine (

113 The flavoenzyme monoamine oxidase (MAO) regulates mammalian behavioral p

114 lamine), which is a monoamine metabolized by monoamine oxidase (MAO), exists widely in plants, animal

115 Tryptophan hydroxylase (TPH1) and monoamine oxidase (MAO-A) are the key enzymes for the sy

116 Drug interaction between inhibitors of monoamine oxidase (MAOIs) and selective serotonin (5-hyd

117 However, it has been reported that monoamine oxidase A (MAO A, a major neurotransmitter-deg

118 Monoamine oxidase A (MAO-A) is an important brain enzyme

119 Monoamine oxidase A (MAO-A) is an important enzyme on th

120 o counter the effects of the 40% increase in monoamine oxidase A (MAO-A) levels that occurs during PP

121 One such biological abnormality is elevated monoamine oxidase A (MAO-A) levels, which occurs in the

122 Monoamine oxidase A (MAOA) activity was associated with

123 g RNA (lncRNA), acting as a regulator of the monoamine oxidase A (MAOA) gene in the brain, and named

124 (5HT) and the monoamine-metabolizing enzyme monoamine oxidase A (MAOA) have been repeatedly implicat

125 y, we identify for the first time a role for monoamine oxidase A (MAOA) in NPC.

126 We report that monoamine oxidase A (MAOA) is a clinically and functiona

127 Monoamine oxidase A (MAOA) is a mitochondrial enzyme tha

128 The rs1137070 polymorphism of monoamine oxidase A (MAOA) is associated with alcoholism

129 ohorts of Finnish prisoners, revealed that a monoamine oxidase A (MAOA) low-activity genotype (contri

130 g growth differentiation factor-3 (GDF3) and monoamine oxidase A (MAOA) that is known to degrade nora

131 6 member 2 (SLC6A2), an NE transporter, and monoamine oxidase A (MAOA), a degradation enzyme.

132 Monoamine oxidase A (MAOA), a mitochondria-bound enzyme,

133 cancer (PCa) exhibit increased expression of monoamine oxidase A (MAOA), a mitochondrial enzyme that

134 Here, we show that upregulation of monoamine oxidase A (MAOA), a mitochondrial enzyme that

135 rine secretion; P < 0.01), with no effect on monoamine oxidase A (serotonin catabolism), serotonin re

136 NIRKO mice also exhibit increased levels of monoamine oxidase A and B (MAO A and B) leading to incre

137 In a screening for potential monoamine oxidase A and B inhibition ciproxifan showed e

138 ted high selectivity (>160x) against related monoamine oxidase A and B.

139 form (sVAP-1) accounts for most circulating monoamine oxidase activity, has insulin-like effects, an

140 o competitive MPP(+)-dependent inhibition of monoamine oxidase activity.

141 (AD), i.e., acetylcholinesterase (AChE) and monoamine oxidase B (MAO B), a series of multitarget lig

142 A set of drugs was further studied in monoamine oxidase B (MAO-B) and cyclooxygenase-1 (COX-1)

143 l) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) at the conventional dose (10

144 Illudinine was found to inhibit monoamine oxidase B (MAO-B) with an IC(50) of 18 +/- 7.1

145 e, competitive, and reversible inhibitors of monoamine oxidase B (MAO-B).

146 was found to suppress the gene expression of monoamine oxidase B (MAOB) in the brain of wild-type but

147 tural comparisons with human metabolites and monoamine oxidase B (MAOB) was identified as the putativ

148 example of a biorelevant synthetic model for monoamine oxidase B activity.

149 onoamine oxidases with slight preference for monoamine oxidase B in both species.

150 hydrogen peroxide (H(2)O(2)) originated from monoamine oxidase B in severe reactive astrocytes causes

151 We report the effects of the addition of a monoamine oxidase B inhibitor, rasagiline, to antidepres

152 est placebo-controlled clinical trial of the monoamine oxidase B inhibitor, rasagiline, we examined h

153 his, a number of highly potent and selective monoamine oxidase B inhibitors were identified.

154 dowed with potent, selective, and reversible monoamine oxidase B inhibitory activity is a clinically

155 Accordingly, monoamine oxidase blockers pargyline and l-deprenyl had

156 mine (2, MBA236) as a new cholinesterase and monoamine oxidase dual inhibitor.

157 MAOB, a crucial monoamine oxidase for dopamine metabolism, triggers oxid

158 Myelosuppression and monoamine oxidase inhibition (MAOI) are key independent

159 iggers lethal phenethylamine poisoning after monoamine oxidase inhibitor administration.

160 While tricyclic and monoamine oxidase inhibitor medications were associated

161 Monoamine oxidase inhibitors (MAOIs) exert therapeutic a

162 ects on outcomes compared with waitlist were monoamine oxidase inhibitors (SMD -1.01, 95% credible in

163 ts [TCA], atypical antidepressants [AA], and monoamine oxidase inhibitors [MAOI]), age, sex, smoking,

164 idepressants (eg, tricyclic antidepressants, monoamine oxidase inhibitors) were excluded.

165 reated with beta-blockers, ACE inhibitors or monoamine oxidase inhibitors, in children under 5 years

166 and several related synthetic analogues are monoamine oxidase inhibitors, which is the first reporte

167 es was synthesized and screened toward human monoamine oxidase isoforms (hMAO-A and hMAO-B).

168 The flavin-dependent monoamine oxidase LSD1 (lysine-specific demethylase 1, a

169 g sites for [(18)F]AV-1451, such as neuronal monoamine oxidase or neuromelanin.

170 re, we demonstrate that AMX-2 is the primary monoamine oxidase that metabolizes 5-HT in C. elegans, a

171 to 3,4-dihydroxymandelic acid (DHMA) by the monoamine oxidase TynA and the aromatic aldehyde dehydro

172 ptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine

173 gether with organic cation transporter 3 and monoamine oxidase type B, two key proteins for DA uptake

174 cascade consisting of the ATHase, the GDH, a monoamine oxidase, and a catalase leads to the productio

175 d by the transaminase is not affected by the monoamine oxidase, and highlights the potential of this

176 ine oxidase, copper containing 3), a surface monoamine oxidase, as a new marker of myofibroblasts by

177 r has been reported to bind to neuromelanin, monoamine oxidase, calcifications, iron, leptomeningeal

178 ethyl transferase (COMT) and two isoforms of monoamine oxidase--modulated degree of belief learning a

179 ompanied by an increase in the expression of monoamine oxidase-A (MAO-A) and MAO-B in the lateral OFC

180 Monoamine oxidase-A (MAO-A) is a treatment target in neu

181 Here we report that high expression of monoamine oxidase-A (MAO-A) is associated with positive

182 study examined how the mitochondrial enzyme monoamine oxidase-A (MAO-A), which produces hydrogen per

183 eas was similarly modulated by inhibition of monoamine oxidase-A and was reduced in animals with indu

184 R antagonist or after incubation with MAO-A (monoamine oxidase-A).

185 -serotonin and increased after inhibition of monoamine oxidase-A, the main enzyme responsible for ser

186 Monoamine oxidase-B inhibitors and dopamine agonists can

187 Measuring monoamine oxidase-B with neuroimaging and glial fibrilla

188 arins were designed, prepared, and tested as monoamine oxidases (MAOs) and acetyl- and butyryl-cholin

189 The resurgence of interest in monoamine oxidases (MAOs) has been fueled by recent corr

190 carbonyl reductases (CREDs), hydrolases and monoamine oxidases (MAOs), providing a comprehensive ove

191 ty towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H3 recep

192 enine dinucleotide (FAD) dependent family of monoamine oxidases and is vital in regulation of mammali

193 As the H3R and monoamine oxidases are all capable of affecting neurotra

194 M1 family is homologous to the mitochondrial monoamine oxidases MAO-A/B and produces hydrogen peroxid

195 omolar concentration range for human and rat monoamine oxidases with slight preference for monoamine

196 and tested for inhibitory activities against monoamine oxidases.

197 terases, N-methyl-D-aspartate receptors, and monoamine oxidases.

198 PPB, a dietary supplement kit consisting of monoamine precursor amino acids and dietary antioxidants

199 2-AG also inhibits locomotion in remodeled monoamine receptor mutant animals designed to measure th

200 This monoamine-receptor activity causes pericytes to locally

201 oxia owing to paradoxical excess activity of monoamine receptors (5-HT1) on pericytes, despite the ab

202 ervated by monoamines, and drugs that target monoamine receptors have been used to treat a number of

203 Inhibition of monoamine receptors or of AADC, or even an increase in i

204 that the loss of the kinase may dysregulate monoamine receptors within these neurons, whose activity

205 Non-classical monoamine recognition evolved in two steps: an ancestral

206 aggression, but a mechanistic account of how monoamines regulate antisocial motives remains elusive.

207 This mechanism may extend to monoamine release in central neurons or in the enteric n

208 may mediate pro-social effects by modulating monoamine release in limbic and cortical areas, which wa

209 DA, confirming the direct effects of 2-AG on monoamine release.

210 ylenedioxymethamphetamine (MDMA) is a potent monoamine releaser that produces an acute euphoria in mo

211 MDMA, a potent monoamine-releaser with particularly pronounced serotoni

212 Receptor activation in the absence of monoamines results from the production of trace amines (

213 dosing with dasotraline, a long-acting, dual monoamine reuptake inhibitor, may be a safe and efficaci

214 s a novel neurogenic compound independent of monoamine reuptake pathways.

215 Monoamine serotonin (5HT) has been linked to aggression

216 The membrane transporters for the monoamines serotonin (SERT) and dopamine (DAT) are promi

217 The monoamines serotonin and dopamine are key regulators of

218 nduced by brainstem neurons that release the monoamines serotonin and noradrenaline, and local vessel

219 s such as glutamate, neuromodulators such as monoamines signal changes in firing rate.

220 developmental periods that are sensitive to monoamine signaling and impact adult behaviors of releva

221 Here we test the hypothesis that increased monoamine signaling during development causes these para

222 nction as a consequence of increased P22-P41 monoamine signaling might underlie altered aggression.

223 icinus lipocalins have the potential to bind monoamines similar to other tick species previously repo

224 The clinically safe monoamine stabilizer (-)-OSU6162 (OSU6162) restores dopa

225 s in specific defects in peptide hormone and monoamine storage and regulated secretion.

226 heir cognate substrates and sustain cellular monoamine stores even during neuronal activity.

227 al fluid-contacting (CSF-c) cells containing monoamines such as dopamine (DA) and serotonin (5-HT) oc

228 tion of hindbrain patterning genes can alter monoamine system development and thereby produce forebra

229 The monoamine system in the prefrontal cortex has been impli

230 neuropsychiatric disorders, we characterized monoamine systems in relation to forebrain neurogenesis

231 lsivity and motivation relative to PFC-based monoamine systems.

232 ress, facilitates apoptosis, and metabolizes monoamines, therapeutics opposing these processes are pr

233 siology of depression, a paradigm shift from monoamine to glutamatergic neurotransmission, thus makin

234 amily of transporters, mediates transport of monoamines to synaptic vesicles and storage organelles i

235 Current monoamine transmission modulating therapeutics, even wit

236 the effort-related effects of the vesicular monoamine transport (VMAT-2) inhibitor tetrabenazine (TB

237 iduals with BPD and leads to marked increase monoamine transport in vitro.

238 ro, with the Ile allele leading to increased monoamine transport into presynaptic vesicles.

239 hus, current knowledge about the kinetics of monoamine transport is sufficiently detailed to provide

240 afficking domain of the Drosophila vesicular monoamine transporter (DVMAT), which is required for the

241 Monoamine transporter (MAT) ligands that allosterically

242 cation 3 transporter (OCT3)/plasma membrane monoamine transporter (PMAT) inhibitor, increased the 5-

243 ed bacterial homologues of the rat vesicular monoamine transporter (rVMAT2).

244 pharmacological inhibition of the vesicular monoamine transporter (VMAT) blocks amphetamine-induced

245 Vesicular monoamine transporter (VMAT), a member of the largest su

246 hloroamphetamine (pCA), acting via vesicular monoamine transporter (VMAT), and a charged VMAT, substr

247 repinephrine transporter (NET) and vesicular monoamine transporter (VMAT-1) was evaluated immunohisto

248 s demonstrate that the presynaptic vesicular monoamine transporter 1 (VMAT1) Thr136Ile (rs1390938) po

249 TH1-S31E associated with vesicular monoamine transporter 2 (VMAT2) and alpha-synuclein in n

250 We previously reported that the vesicular monoamine transporter 2 (VMAT2) is physically and functi

251 neurons projecting to the LHb lack vesicular monoamine transporter 2 (VMAT2) mRNA, and there is littl

252 lacetic acid (DOPAC)/DA ratio, and vesicular monoamine transporter 2 (VMAT2) protein.

253 e neurotransmitter 200 (FFN200), a vesicular monoamine transporter 2 (VMAT2) substrate that selective

254 coordinated activity of astroglial vesicular monoamine transporter 2 (VMAT2) together with organic ca

255 for the serotonin transporter and vesicular monoamine transporter 2 (VMAT2).

256 AC)-mediated overexpression of the vesicular monoamine transporter 2 (VMAT2; Slc18a2).

257 than the dopamine transporter and vesicular monoamine transporter 2 defects, suggesting upregulation

258 8854) is a novel, highly selective vesicular monoamine transporter 2 inhibitor that demonstrated favo

259 omography (PET) radioligand to the vesicular monoamine transporter 2, (VMAT2), [(11)C]dihydrotetraben

260 ncludes tyrosine hydroxylase (TH), vesicular monoamine transporter 2, and the norepinephrine transpor

261 d genes tyrosine hydroxylase (TH), vesicular monoamine transporter 2, dopamine transporter and aldehy

262 cular acetylcholine transporter or vesicular monoamine transporter 2.

263 Although an influence of CAPS on monoamine transporter function and on vesicle acidificat

264 an antidepressive agent and a non-selective monoamine transporter inhibitor that blocks the reuptake

265 Dichloropane, a monoamine transporter ligand, enables targeting of dense

266 ethylenedioxyamphetamine analogs bind at the monoamine transporter orthosteric binding site by adopti

267 on reveals the subcellular distribution of a monoamine transporter protein in the axons of a single,

268 requires metabolism to the amphetamine-like monoamine transporter substrate phenmetrazine (PM) to pr

269 Vesicular monoamine transporter type 2 (VMAT2) imaging with PET al

270 ([(11)C]DTBZ) binding to striatal vesicular monoamine transporter type 2 (VMAT2) in cocaine abusers

271 The vesicular monoamine transporter type 2 (VMAT2), an important regul

272 BZ), a novel radiotracer targeting vesicular monoamine transporter type 2 (VMAT2), has been proven as

273 toradiographic measures of DAT and vesicular monoamine transporter type 2 (VMAT2), striatal dopamine,

274 The mean reductions of vesicular monoamine transporter type 2 density for the caudate, pu

275 hydrotetrabenazine (DTBZ; reflects vesicular monoamine transporter type 2), ex vivo quantification of

276 ministration of the VMAT-2 (type-2 vesicular monoamine transporter) inhibitor tetrabenazine (9,10-dim

277 doses of deutetrabenazine-a novel vesicular monoamine transporter-2 inhibitor-in patients with tardi

278 rboxylase, the DA transporter, and vesicular monoamine transporter-2 with EGFP in midbrain dopaminerg

279 ster ovary cells expressing either vesicular monoamine transporter.

280 in receptors (e.g., serotonin receptors) and monoamine transporters (i.e., serotonin, dopamine, and n

281 Monoamine transporters (MATs) regulate neurotransmission

282 pports the concept that uptake and efflux at monoamine transporters are asymmetric processes that can

283 C, and HHMC were substrate-type releasers at monoamine transporters as determined in vitro, but only

284 The plasmalemmal monoamine transporters clear the extracellular space fro

285 loiting structural templates known to target monoamine transporters for dopamine, norepinephrine, and

286 esults provide new insights into the role of monoamine transporters in autophagy regulation and ident

287 nal activities of the compounds at all three monoamine transporters in native brain tissue and cells

288 that define substrates and inhibitors at the monoamine transporters is critical to elucidating the me

289 The serotonin transporter (SERT) and other monoamine transporters operate in either a forward trans

290 ate fast-acting currents, I suggest that the monoamine transporters should be considered as ionotropi

291 ed pore" mechanism in the mammalian synaptic monoamine transporters, and the archaeal GltPh, which is

292 r (LeuT) is a bacterial homolog of the human monoamine transporters, which are important pharmaceutic

293 king mechanism is unique to DAT or common to monoamine transporters.

294 eads to increased activity of both vesicular monoamine transporters.

295 y-five studies (29 DAT, 6 AADC, no vesicular monoamine type 2 studies) with 356 MSA-P patients, 204 P

296 drotetrabenazine ((11)C-DTBZ) is a vesicular monoamine type 2 transporter PET ligand that allows asse

297 mino acid decarboxylase (AADC), or vesicular monoamine type 2 were investigated.

298 with two clinically relevant compounds: the monoamine uptake inhibitor bupropion and the dopamine an

299 e ability of acute administration of various monoamine uptake inhibitors to reverse the effects of TB

300 tive action of acetylcholine (ACh), GABA and monoamines, which lead to transitions between primary br